European healthcare systems need to improve in terms of efficiency, according to the European Union's European Semester Country Specific Recommendations published yesterday. The EU commitment to ensuring equity of access to healthcare is challenged by the limited financial capacity of governments to cover growing demand for healthcare services. Generic and biosimilar medicines provide the greatest opportunity to improve access to safe and effective medicines through efficient medicines policies. Governments should adopt medicines policies that support the use of generic and biosimilar medicines to generate the sustained benefits of competition over the long-term. Short-sighted and radical cost-containment measures (such as External Reference Pricing (ERP), single winner tendering, payback/clawback policies and mandated price cuts), endanger medicines supply reliability and ultimately patient health, as is underlined in the Commission’s assessment of the situation in Romania. Adrian van den Hoven, Director General at Medicines for Europe commented: “The OECD, the European Commission, and the European Council have highlighted the importance of the timely availability of generic and biosimilar medicines for healthcare systems. "In this light," van den Hoven added, "Medicines for Europe has developed a set of Country Recommendations for France, Italy, The Netherlands, Spain, Portugal, Bulgaria and Ireland to help the EU and member states develop effective policies that support access to medicines for patients”. To fully realize the potential of generic and biosimilar medicines, Medicines for Europe recommend that European governments should encourage competition from generic and biosimilar medicines based on four overarching recommendations as well as specific measures for each country:
More details on the Medicines for Europe recommendations can be found
here
.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.